Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases
L. Bianchi
Departments of Dermatology and Anatomical Pathology, Tor Vergata University of Rome, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
Search for more papers by this authorA. Orlandi
Departments of Dermatology and Anatomical Pathology, Tor Vergata University of Rome, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
Search for more papers by this authorE. Campione
Departments of Dermatology and Anatomical Pathology, Tor Vergata University of Rome, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
Search for more papers by this authorC. Angeloni
Departments of Dermatology and Anatomical Pathology, Tor Vergata University of Rome, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
Search for more papers by this authorA. Costanzo
Departments of Dermatology and Anatomical Pathology, Tor Vergata University of Rome, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
Search for more papers by this authorL.G. Spagnoli
Departments of Dermatology and Anatomical Pathology, Tor Vergata University of Rome, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
Search for more papers by this authorS. Chimenti
Departments of Dermatology and Anatomical Pathology, Tor Vergata University of Rome, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
Search for more papers by this authorL. Bianchi
Departments of Dermatology and Anatomical Pathology, Tor Vergata University of Rome, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
Search for more papers by this authorA. Orlandi
Departments of Dermatology and Anatomical Pathology, Tor Vergata University of Rome, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
Search for more papers by this authorE. Campione
Departments of Dermatology and Anatomical Pathology, Tor Vergata University of Rome, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
Search for more papers by this authorC. Angeloni
Departments of Dermatology and Anatomical Pathology, Tor Vergata University of Rome, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
Search for more papers by this authorA. Costanzo
Departments of Dermatology and Anatomical Pathology, Tor Vergata University of Rome, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
Search for more papers by this authorL.G. Spagnoli
Departments of Dermatology and Anatomical Pathology, Tor Vergata University of Rome, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
Search for more papers by this authorS. Chimenti
Departments of Dermatology and Anatomical Pathology, Tor Vergata University of Rome, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
Search for more papers by this authorL.B. and A.O. have contributed to equally this work.
Summary
Background Basal cell carcinoma (BCC) is the most common cancer in humans. Medical treatment modalities offer cost reductions and clinical advantages in selected cases such as low-risk areas, surgically inaccessible sites, patients with multiple neoplasms, and older, infirm or anticoagulated subjects. Tazarotene has been proposed for the treatment of BCC; however, data on its efficacy are lacking.
Objectives To investigate the efficacy of tazarotene in a large series of BCCs, better to define the clinical advantages and the mechanisms of action in vivo.
Methods Tazarotene 0·1% gel was applied daily for 24 weeks to 154 small superficial and nodular BBCs. Clinicopathological changes were followed during the therapy by dermoscopic and histological examination. Proliferation, retinoic acid receptors and apoptosis were investigated by immunohistochemistry and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labelling on biopsies.
Results At 24 weeks of therapy, 70·8% of the BCCs showed > 50% clinical and dermoscopic regression, and 30·5% healed without recurrences after 3 years of follow-up. At 12 weeks, biopsies showed that regression was associated with reduced proliferation and increased apoptosis of basaliomatous cells. Most unresponsive tumours displayed a keratotic differentiation.
Conclusions Tazarotene was effective in the majority of superficial and nodular undifferentiated BCCs treated, possibly by antiproliferative and proapoptotic actions in vivo. Keratotic BCCs were the major type among the unresponsive tumours, and were characterized by overexpression of p53 and cellular retinol binding protein-1 in comparison with undifferentiated tumours. Topical tazarotene represents an alternative medical choice for selected cases of BCC.
References
- 1 Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146 (Suppl. 61): 1–6.
- 2 Wennberg AM. Basal cell carcinoma—new aspects of diagnosis and treatment. Acta Derm Venereol Suppl (Stockh) 2000; 209: 5–25.
- 3 Reymann F. Basal cell carcinoma of the skin recurrence rate after different types of treatment: a review. Dermatologica 1980; 161: 217–26.
- 4 Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15: 315–28.
- 5 Thissen MRTM, Neumann MHA, Schouten LJ. A systemic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135: 1177–83.
- 6 Marghoob AA. Basal and squamous cell carcinomas: what every primary care physician should know. Postgrad Med 1997; 102: 139–59.
- 7 Martinez JC, Otley CC. The management of melanoma and nonmelanoma skin cancer: a review for the primary care physician. Mayo Clin Proc 2001; 76: 1253–63.
- 8 Vine JE. Skin cancer update. Treatment alternatives for basal-cell and squamous-cell carcinoma. N J Med 2001; 98: 35–7.
- 9 Vander Straten M, Lee P, Weitzul S et al. Advances in the treatment of basal cell carcinoma: the promise of pharmacologic therapy. Adv Dermatol 2000; 16: 299–318.
- 10 Urosevic M, Dummer R. Immunotherapy for nonmelanoma skin cancer: does it have a future? Cancer 2002; 94: 477–85.
- 11 Buechner SA, Wernil M, Harr T et al. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J Clin Invest 1997; 100: 2691–6.
- 12 Gibbs P, Gonzalez R, Lee LA, Walsh P. Medical management of cutaneous malignancies. Clin Dermatol 2001; 19: 298–304.
- 13 Urosevic M, Maier T, Benninghoff B et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003; 139: 1325–32.
- 14 Bastiaens MT, Hoefnagel JJ, Bruijn JA et al. Differences in age, site distributions, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J Invest Dermatol 1998; 110: 880–4.
- 15 Love JM, Gudas LJ. Vitamin A, differentiation and cancer. Curr Opin Cell Biol 1994; 6: 825–31.
- 16 Lotan R. Retinoids in cancer chemoprevention. FASEB J 1996; 10: 1031–9.
- 17 Napgal S, Chandraratna RA. Recent development in receptor-selective retinoids. Curr Pharm Des 2000; 6: 919–31.
- 18 Chandraratna RA. Future trends: a new generation of retinoids. J Am Acad Dermatol 1998; 39: S149–52.
- 19 Chandraratna RA. Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol 1997; 37: S12–7.
- 20 Thacher SM, Vasudevan J, Chandraratna RA. Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des 2000; 6: 25–58.
- 21
Peris K,
Fargnoli MC,
Chimenti S.
Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma.
N Engl J Med
1999; 341: 1767–8.
10.1056/NEJM199912023412312 Google Scholar
- 22 Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493–501.
- 23 Spagnoli LG, Orlandi A, Santeusanio G. Foam cells of the rabbit atherosclerotic plaque arrested in metaphase by colchicine show a macrophage phenotype. Atherosclerosis 1991; 88: 87–92.
- 24 Elder D, Elenitsas R, Jaworsky C, Johnson B Jr, eds. Lever's Histopathology of the Skin, 8th edn. Philadelphia: Lippincott-Raven, 1997.
- 25 Kamradt J, Reichrath J. Expression of retinoic acid receptor proteins in basal cell carcinomas: an immunohistochemical analysis. J Histochem Cytochem 1996; 44: 1415–20.
- 26 Stockfleth E, Sterry W. New treatment modalities for basal cell carcinoma. Recent Results Cancer Res 2002; 160: 259–68.
- 27 Widschwendter M, Berger J, Daxenbichler G et al. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res 1997; 57: 4158–61.
- 28 Khuri FR, Lotan R, Kemp BL et al. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol 2000; 18: 2798–804.
- 29
Li Y,
Dawson MI,
Agadir A et al.
Regulation of RAR beta expression by RAR- and RXR-selective retinoids in human lung cancer cell lines: effect on growth inhibition and apoptosis induction.
Int J Cancer
1998; 75: 88–95.
10.1002/(SICI)1097-0215(19980105)75:1<88::AID-IJC14>3.0.CO;2-9 CAS PubMed Web of Science® Google Scholar
- 30 Sun SY, Wan H, Yue P et al. Evidence that retinoic acid receptor beta induction by retinoids is important for tumor cell growth inhibition. J Biol Chem 2000; 275: 17149–53.
- 31 Orlandi A, Bianchi L, Costanzo A et al. Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene. J Invest Dermatol 2004; 122: 1037–41.
- 32 De Luca LM. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 1991; 5: 2924–33.
- 33 Xu XC, Lee JS, Lee JJ et al. Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention. J Natl Cancer Inst 1999; 91: 1317–21.
- 34 Gebert JF, Moghal N, Frangioni JV et al. High frequency of retinoic acid receptor beta abnormalities in human lung cancer. Oncogene 1991; 6: 1859–68.
- 35 Raffo P, Emionite L, Colucci L et al. Retinoid receptors: pathways of proliferation inhibition and apoptosis induction in breast cancer cell lines. Anticancer Res 2000; 20: 1535–43.
- 36 Huang DC, Adams JM, Cory S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J 1998; 17: 1029–39.
- 37 Miyashita T, Krajewski S, Krajewska M et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799–805.
- 38 Barrett TL, Smith KJ, Hodge JJ et al. Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma. J Am Acad Dermatol 1997; 37: 430–7.
- 39 Campbell C, Quinn AG, Ro YS et al. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J Invest Dermatol 1993; 100: 746–8.
- 40 Ong DE, Newcomer ME, Chyntil F. Cellular retinoid-binding proteins. In: The Retinoids: Biology, Chemistry and Medicine ( MB Sporn, AB Roberts, DS Goodman, eds). New York: Raven Press, 1994; 283–317.
- 41 Husmann M, Hoffmann B, Stump DG et al. A retinoic acid response element from the rat CRBP-I promoter is activated by an RAR/RXR heterodimer. Biochem Biophys Res Commun 1992; 187: 1558–64.
- 42 Boerman MH, Napoli JL. Cellular retinol-binding protein supported retinoic acid synthesis. Relative roles of microsomes and cytosol. J Biol Chem 1996; 271: 5610–6.
